Monitor for topline data in early Q2 2027, which is the next major catalyst. No financial data or guidance changes here — the stock will likely trade on pipeline sentiment and broader biotech sector trends until then.
Price Chart
Executive Summary
Coya Therapeutics announced that the 100th patient has been enrolled in its Phase 2/3 ALSTARS trial (COYA 302 for ALS), with full enrollment of 120 participants expected in time for topline data in early Q2 2027. This is a routine operational update on a pre-revenue clinical-stage biotech, providing a modest derisking of the trial timeline but no financial data or efficacy results.
Key Facts
- 100th patient enrolled in Phase 2/3 ALSTARS trial (NCT07161999) evaluating COYA 302 for ALS.
- Full enrollment of 120 participants anticipated in time to report topline data in early Q2 2027.
- Trial is randomized, double-blind, placebo-controlled with two dosing regimens and a 24-week primary endpoint (ALSFRS-R).
- No financial data, revenue, earnings, or cash runway figures were disclosed in the filing.
Financial Impact
No financial figures disclosed in the filing. Pre-revenue clinical-stage company with $109M market cap.
Risk Factors
- Clinical trial failure risk — COYA 302 may not meet its primary endpoint.
- Pre-revenue company with no approved products; relies on capital markets for funding.
- Enrollment or data timeline could slip beyond early Q2 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-391378 |
| Document: 0001193125-26-391378-index-headers.html | 0001193125-26-391378 |
| Document: 0001193125-26-391378-index.html | 0001193125-26-391378 |
| Document: 0001193125-26-391378.txt | 0001193125-26-391378 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $4.18 | awaiting T+20 | — | $4.12 (−1.44%) |
Oct 5, 2026 22d ago | 8-K | $4.85 | awaiting T+20 | — | $4.12 (−15.05%) |
Sep 15, 2026 6w ago | 8-K | $4.65 $4.48 | ▼ −3.76% | ▼ −6.74% | $4.12 (−11.40%) |
Aug 11, 2026 11w ago | 8-K | $4.80 $4.61 | ▼ −3.96% | ▼ −2.90% | $4.12 (−14.17%) |
May 12, 2026 24w ago | 8-K | $4.29 $4.41 | ▲ +2.80% | ▲ +4.52% | $4.12 (−3.96%) |
Apr 2, 2026 29w ago | 8-K | $4.01 $4.23 | ▲ +5.49% | ▼ −4.39% | $4.12 (+2.74%) |
Mar 23, 2026 31w ago | EFFECT | $4.22 $4.53 | ▲ +7.35% | ▼ −0.07% | $4.12 (−2.37%) |
Mar 16, 2026 32w ago | S-3 | $4.50 $4.46 | ▼ −0.89% | ▼ −4.67% | $4.12 (−8.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers